Factors associated with endometrial pathology during tamoxifen therapy in women with breast cancer: a retrospective analysis of 821 biopsies

[1] Davies C(1988)Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. an overview of 61 randomized trials among 28,896 women N Engl J Med 319 1681-1692

[2] Cohen I(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-1717

[3] Dijkhuizen FP(2013)Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Lancet 381 805-816

[4] Lahti E(2004)Endometrial pathologies associated with postmenopausal tamoxifen treatment Gynecol Oncol 94 256-266

[5] Cohen I(1996)Transvaginal ultrasonography and endometrial changes in postmenopausal breast cancer patients receiving tamoxifen Maturitas 25 45-50

[6] Stewart HJ(1993)Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen Obstet Gynecol 81 660-664

[7] Knight GM(1994)Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients Gynecol Oncol 52 185-190

[8] Deligdisch L(1989)Tamoxifen and the uterus and endometrium Lancet 1 375-376

[9] Sismondi P(2000)Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer Gynecol Oncol 78 181-186

[10] Fisher B(1994)Tamoxifen and endometrial cancer Ann N Y Acad Sci 734 310-321

[1] Davies C(1988)Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. an overview of 61 randomized trials among 28,896 women N Engl J Med 319 1681-1692

[2] Cohen I(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-1717

[3] Dijkhuizen FP(2013)Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Lancet 381 805-816

[4] Lahti E(2004)Endometrial pathologies associated with postmenopausal tamoxifen treatment Gynecol Oncol 94 256-266

[5] Cohen I(1996)Transvaginal ultrasonography and endometrial changes in postmenopausal breast cancer patients receiving tamoxifen Maturitas 25 45-50

[6] Stewart HJ(1993)Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen Obstet Gynecol 81 660-664

[7] Knight GM(1994)Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients Gynecol Oncol 52 185-190

[8] Deligdisch L(1989)Tamoxifen and the uterus and endometrium Lancet 1 375-376

[9] Sismondi P(2000)Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer Gynecol Oncol 78 181-186

[10] Fisher B(1994)Tamoxifen and endometrial cancer Ann N Y Acad Sci 734 310-321